PubMed Health⌕ Search

PubMed · 3057633

Endothelium: from whence to whither.

Abstract

Today's perspective of the endothelial cell recognizes its real significance, heretofore neglected, and anticipates important future contributions to improved medical management. Like trustworthy posted guards of the vascular frontier, endothelial cells oversee and regulate not only fluid and solute traffic (between lumen and tissue) but also contribute valuable protective forces to act at each of its boundaries. Uniquely different from its guardian colleague, the nonnucleated platelet lacks ability to regenerate blocked metabolic functions (for example, thromboxane production), whereas the nucleated endothelial cell is metabolically complete and therefore able to regenerate blocked metabolic functions (for example, PGI2 production). The endothelial cell commands and modulates the circulation, regulating the contractility of its underlying smooth musculature and the rheologic properties of its overlying circulating fluid. Many overlooked contributions of the endothelial cells, from its luminal, abluminal, and abutting surfaces, modulate important, even critical, physiologic functions. Only very recently have management techniques begun to exploit these endothelial functions; but developing new techniques promise exciting therapeutic possibilities soon. As we look to that future, we must apply our knowledge to coronary artery disease, congestive heart failure, cerebrovascular disease, thromboembolism, diabetic degenerative disease, hemolytic uremic syndrome, shock lung, vasospastic disorders, and a great variety of other today's inadequately managed disorders of man and animals.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W H Wehrmacher. 1988. Endothelium: from whence to whither.. https://pubmed.ncbi.nlm.nih.gov/3057633/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Statins in heart failure. Beyond the lipid lowering effect.

Statins, the most widely prescribed medications in patients with hyperlipidemia and coronary heart disease, have a number of pleiotropic actions beyond cholesterol lowering. They improve endothelial function, they have antioxidant and anti-inflammatory effects, they regulate neovascularization and have immunomodulatory activities. Experimental evidence suggests that statins may be beneficial in heart failure as they can inhibit myocardial hypertrophy, reduce cardiomyocyte loss by apoptosis, reduce oxidative stress and restore neurohormonal imbalance. Furthermore small randomised clinical trials showed that short term statin administration may improve key pathophysiological aspects of this syndrome. Finally retrospective analyses of large statin trials imply a long term profit on clinical outcome in this group of patients. These results however need to be reviewed with caution as certain studies have demonstrated that low serum cholesterol is associated with worse prognosis in HF and that ubiquinone levels, a micronutrient with antioxidant actions, reduces significantly following statin administration. Large prospective randomised controlled trials are needed to confirm the beneficial effect of statins on cardiovascular outcome in HF patients and further elucidate the contributing mechanisms. Finally the statin dose and the interaction with co-administered drugs need to be studied.

Endothelium, Vascular↗